Dianthus Therapeutics Inc [DNTH] stock is trading at $34.03, down -2.72%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DNTH shares have gain 1.52% over the last week, with a monthly amount drifted -2.60%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dianthus Therapeutics Inc [NASDAQ: DNTH] stock has seen the most recent analyst activity on October 14, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $56. On December 20, 2024, TD Cowen initiated with a Buy rating. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $48 on October 03, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $58 as its price target on July 26, 2024. In a note dated May 16, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $40 on this stock.
Dianthus Therapeutics Inc [DNTH] stock has fluctuated between $13.36 and $40.16 over the past year. Currently, Wall Street analysts expect the stock to reach $69 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $34.03 at the most recent close of the market. An investor can expect a potential return of 102.76% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
Dianthus Therapeutics Inc [NASDAQ:DNTH] reported sales of 4.85M for the trailing twelve months, which represents a drop of -89.64%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -26.77%, Pretax Profit Margin comes in at -23.64%, and Net Profit Margin reading is -23.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.35 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.41 points at the first support level, and at 30.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.53, and for the 2nd resistance point, it is at 37.02.
Ratios To Look Out For
For context, Dianthus Therapeutics Inc’s Current Ratio is 13.12. In addition, the Quick Ratio stands at 13.12 and the Cash Ratio stands at 0.66. Considering the valuation of this stock, the price to sales ratio is 279.37, the price to book ratio is 3.61.
Transactions by insiders
Recent insider trading involved Savitz Ryan, CFO & CBO, that happened on Sep 09 ’25 when 20000.0 shares were sold. Officer, RYAN SAVITZ completed a deal on Sep 09 ’25 to buy 20000.0 shares.
